$TNDM

TANDEM DIABETES CARE INC

Tandem Diabetes Care designs, develops and commercializes insulin delivery systems and diabetes technology for people with insulin-dependent diabetes. Its pump platforms include t:slim X2 and Tandem Mobi, which can be used with continuous glucose monitoring sensors as automated insulin delivery systems powered by Control-IQ+ technology. Tandem also sells single-use pump supplies, including insulin cartridges and infusion sets. Its software and data offerings include the Tandem Device Updater, the Tandem Source web platform for therapy data, and the Sugarmate mobile app. Tandem makes money by selling pumps and replacement supplies, and offers software updates to in-warranty customers at no cost. Its technology is available in more than 25 countries. In the United States and Canada, Tandem uses direct sales, customer support and clinical teams, with independent distributors handling order fulfillment. Its pumps are assembled, tested and packaged at its facilities in San Diego, California.

AlphAI earnings readThird Quarter 2026 · NOV 5Tandem Diabetes Care Announces Third Quarter 2026 Financial ResultsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

17
0
0
—
$33K
TWOMEY CHRISTOPHER J
100%
See all $TNDM insider activity →

Stifel upgrades Tandem Diabetes stock rating on product pipeline

Stifel upgraded Tandem Diabetes Care (TNDM) to Buy with a $26 price target, citing product pipeline and undervaluation. The stock trades at $17.06, suggesting 50% upside. The company reported Q3 revenue of $284M, beating estimates, and received FDA clearance for its Tandem Mobi device. Mizuho raised its price target to $20.

TNDM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 17 news stories mentioning TNDM (TANDEM DIABETES CARE INC). Coverage has skewed bullish: 17 bullish, 0 neutral, and 0 bearish.

Recent TNDM coverage spans financial news, market movers and regulation.

In the last 30 days, TNDM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($33K). The most active reporter was TWOMEY CHRISTOPHER J with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving TNDM

AlphAI scores every news story that mentions TNDM with an AI model for sentiment and relevance, and aggregates insider trades from TANDEM DIABETES CARE INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TNDM

Score
$TNDMHighAI 8/10

Why is Tandem Diabetes Care stock surging today?

Tandem Diabetes Care (TNDM) stock rose 14.2% after FDA clearance for its tubeless insulin delivery system, with a 2027 U.S. launch planned. Mizuho raised its price target to $20. Q3 2026 revenue was $283.7M, up 13.8% YoY, beating estimates. The move was driven by company-specific news, not broader market trends.

$TNDMMedAI 8/10Clinical / regulatory

Tandem Diabetes Care, Inc. received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless…

TANDEM DIABETES CARE INC (TNDM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear (1) . A n

Related tickers